Dr. Reddy's Drug Sale Extension: Court ne diya 30 Din ka Time! Novo Nordisk Row

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAarav Shah|Published at:
Dr. Reddy's Drug Sale Extension: Court ne diya 30 Din ka Time! Novo Nordisk Row
Overview

Lo bhai, Dr. Reddy's walo ko thodi relief mil gayi hai! Delhi High Court ne unko apne 'Olymviq' drug ka stock clear karne ke liye extra **30 din** ka time de diya hai. Iske baad iska naam badal kar 'Olymra' kar diya jayega.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Court ka Interim Order: Stock Clear Hoga, Waste Nahi!

Delhi High Court ne saaf kar diya hai ki Dr. Reddy's Laboratories apna semaglutide stock 'Olymviq' brand name ke under ab aur 30 din tak bech sakta hai. Court ne kaha ki woh yeh stock ko destroy karne ka order nahi degi, balki company ko manage karke clear karne ka mauka degi. Dr. Reddy's pehle hi court ko bata chuki hai ki woh dispute solve karne ke liye naya brand name propose karne wali hai.

Novo Nordisk Kyun Khush Nahi Hai?

Danish pharma giant Novo Nordisk ne Dr. Reddy's par case kiya tha. Unka kehna tha ki 'Olymviq' naam unke popular drug 'Ozempic' se kaafi milta-julta hai. Novo Nordisk ko dar hai ki isse Indian market mein patients aur doctors confuse ho sakte hain, jisse safety issues bhi aa sakte hain.

India Mein Generic Drugs Ka Scene

Yeh sab tab ho raha hai jab India mein generic semaglutide versions patent khatam hone ke baad aane shuru ho gaye hain. Market mein kai companies saste options laane wali hain, aur aise mein brand name bahut important ho jata hai. Dr. Reddy's apna yeh semaglutide product 'Obeda' naam se bhi bechti hai.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.